Safety and Immunogenicity of Intranasal Razi Cov Pars as a COVID-19 Booster Vaccine in Adults: Promising Results from a Groundbreaking Clinical Trial.

This specific IgA antibody response was demonstrated in all subgroup analyses according to the interval between the last vaccination and the intranasal booster dose (5 to 9.5 months, 9.5 to 12.5 months, and 12.5 to 18 months), main types of the last vaccine received (Razi Cov Pars, Sinopharm and Spikogen), and main types of the primary vaccination (Razi Cov Pars, Sinopharm and AstraZeneca)—even though they did not reach statistical significance due to small numbers in the strata.

also in 111,027 other papers